http://www.incirculation.net/52694_0.aspxBlogen-usDuring the AHA 2011, John McMurray and Paul Armstrong discussed the HOOPS trial – a pharmacist-led primary care intervention, with the aim to reduce hospitalization and death in patients with heart failure. Did this intervention have the outcome that they hoped for? And how can the pharmacist be engaged in patient care?2011-12-12http://www.incirculation.net/52693_121243.aspxFreek Verheugt spoke to InCirculation.net about the TRACER trial. We find out why the sweet spot was not found and ask, have we reached the ceiling of safety of dual antiplatelet therapy?2011-12-12http://www.incirculation.net/52693_121249.aspxMichael Ezekowitz and John Camm discuss the FAST trial. Is Surgical ablation ‘superior’ to catheter ablation in atrial fibrillation?2011-12-12http://www.incirculation.net/52693_121253.aspxKurt Huber discusses the advancing field of genetic profiling, specifically in poor responders to clopidogrel therapy. Will profiling become the clinical norm and what factors remain unknown in the role of genetic profiling in tailoring individual antiplatelet therapy?2011-09-14http://www.incirculation.net/52693_119305.aspxDuring the ESC 2011 meeting in Paris, France, John McMurray gave a round-up of the hot topics in the treatment of patients with heart failure. 2011-09-13http://www.incirculation.net/52693_119283.aspxDuring the ESC 2011 meeting in Paris, France, John Pepper gave a fascinating insight into the continuing development of left-ventricular assist devices.2011-09-12http://www.incirculation.net/52693_119231.aspxDuring the ESC 2011 meeting in Paris, France, Desmond Julian spoke with Aldo Maggioni (ANMCO Research Centre, in Florence, Italy) about the PURE study, which was presented by Salim Yusuf during the first Hot-Line session.2011-09-12http://www.incirculation.net/52693_119219.aspxDuring the ESC 2011 meeting in Paris, France, Desmond Julian spoke with Roger Hall (University of East Anglia, UK) about the ARISTOTLE trial, which evaluated the efficacy of apixaban versus warfarin treatment for patients with atrial fibrillation.2011-09-11http://www.incirculation.net/52693_119223.aspxDuring the ESC 2011 meeting in Paris, France, Desmond Julian interviewed John Pepper (Professor of Cardiac Surgery, Royal Brompton & Harefield, London, UK) about the fast-changing landscape of valvular replacement surgery.2011-09-11http://www.incirculation.net/52693_119227.aspxRoger Hall spoke to Freek Verheugt, an expert in interventional cardiology, about radial versus femoral approach for percutaneous coronary intervention. Should the femoral approach be abandoned in favor of radial?2011-07-29http://www.incirculation.net/52693_118161.aspxRoger Hall spoke to Sidney Goldstein about the best treatment for reducing hypertension in patients with diabetes or impaired glucose tolerance. Are angiotensin II receptor blockers preferential over ACE inhibitors and how can we use this information in the clinic?2011-07-27http://www.incirculation.net/52693_118117.aspxRoger Hall spoke to Sidney Goldstein about the OSCAR trial in elderly Japanese patients with hypertension; what do the results tell us and what do they omit? Should treatment be based on what is most convenient for the patient? 2011-07-21http://www.incirculation.net/52693_117837.aspxInterventional cardiologist, Kurt Huber spoke to Freek Verheugt about the PRECOMBAT trial. Does the trial provide the long-term data needed? And what promise do new developments hold for the future of treatment?2011-07-19http://www.incirculation.net/52693_117787.aspxInterventional cardiologist, Kurt Huber spoke to Freek Verheugt about the EXCELLENT trial and the role of clopidogrel in patients with stents. Does EXCELLENT successfully bring closure to the debate of 12-month versus 6-month clopidogrel therapy?2011-07-08http://www.incirculation.net/52693_117621.aspxOver the last 20 years, owing to the substantial progress made in the management of ACS, bleeding has emerged as an important issue; in relative terms, bleeding is now a more frequent outcome than death or reinfarction. Professor Gabriel Steg discusses the changing challenges of bleeding in ACS, and reminds us that bleeding is not an unpredictable event.2011-07-07http://www.incirculation.net/52693_117583.aspxJohn McMurray discusses the STICH trial results and notes that surgical revascularization does improves long-term cardiovascular mortality and morbidity, although at the expense of a small increase in peri-operative deaths. Roger Hall asks the question; how does this help us in treating our patients?2011-07-05http://www.incirculation.net/52693_117537.aspxBernard Gersh speaks to Roger Hall about the EVEREST II trial and discusses the device and limitations of results. Is the MitraClip a suitable device to rival surgery?2011-06-06http://www.incirculation.net/52693_116855.aspxRoger Hall and Martyn Thomas discuss the cost–effectiveness and quality of life in the cohort B arm of the PARTNER trial. How does the transcatheter aortic valve replacement compare with other procedures in these patients, and can we put a price on extending their lives?2011-06-03http://www.incirculation.net/52693_116817.aspxHow far have we come in understanding the need for cardiovascular disease prevention? Kornelia Kotseva discusses the achievements and shortcomings of the EUROASPIRE and RESPONSE trials and questions if saving people’s lives from acute heart attacks is sufficient.2011-05-20http://www.incirculation.net/52693_116601.aspxRoger Hall discusses the PARTNER trial with Martyn Thomas. How significant are the results and which is the best technique in those with severe, symptomatic aortic stenosis?2011-05-04http://www.incirculation.net/52693_116276.aspx